Key TakeawaysAstraZeneca plans a $570 million investment in Toronto to expand its clinical studies, highlighting Canada’s potential as a life sciences hub.Enhertu received FDA priority review for treating metastatic HER2-positive solid tumors, marking a potential first tumor-agnostic HER2-targeted medicine.AstraZeneca’s 2024 focus included expanding its business through 2030 with new treatments and regulatory approval in Japan […]
